Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820
نویسندگان
چکیده
In the article listed above, the sentence on page 814 that reads “There also were more serious hypoglycemic events in the liraglutide arm and more sulfonylurea and insulin use in the placebo group” has been corrected to read “There was more sulfonylurea and insulin use in the placebo group.” The online version has been corrected to reflect this change. Muhammad Abdul-Ghani, Ralph A. DeFronzo, Stefano Del Prato, Robert Chilton, Rajvir Singh, and Robert E.J. Ryder Diabetes Care 1
منابع مشابه
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 re...
متن کاملErratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331
متن کامل
Erratum. Factors Associated With Diabetes-Specific Health-Related Quality of Life in Youth With Type 1 Diabetes: The Global TEENs Study. Diabetes Care 2017;40:1002—1009
متن کامل
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831
In the article cited above, there are typographical errors in Table 3 with regard to the values for hospitalization for heart failure results. The results should state an incidence of 2.7% (126/4,687) with empagliflozin and 4.1% (95/2,333) with placebo, and the corresponding incidence rates should be 9.4/1,000 patient-years and 14.5/1,000 patient-years, respectively. The HR of 0.65 (95% CI 0.50...
متن کاملEVALUATION OF METABOLIC PROFILE OF PLASMA AMINO ACIDS IN DIABETIC PATIENTS WITH CARDIOVASCULAR DISEASES
Background: Diabetes mellitus is one of the most common endocrine diseases. Cardiovascular disease (CVD) is one of the leading causes of death in patients with type 2 diabetes. The aim of this study was to investigate the metabolic profile of plasma amino acids in diabetic patients with cardiovascular disease. Methods: The present study is a descriptive-analytical cross-sectional study on 140 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 40 شماره
صفحات -
تاریخ انتشار 2017